3-(5-hexenyl)-1-methyluracil | 160279-34-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-(5-hexenyl)-1-methyluracil
• 英文别名: 3-hex-5-enyl-1-methylpyrimidine-2,4-dione
• CAS: 160279-34-5
• 化学式: C₁₁H₁₆N₂O₂
• 分子量: 208.26
• InChiKey: PUXJALKHHNQPLJ-UHFFFAOYSA-N

物化性质

• 沸点：
  311.0±35.0 °C(Predicted)
• 密度：
  1.075±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(5-hexenyl)-1-methyluracil 、 N-甲基吗啉氧化物 、 、 水 、 Sodium Hydrosulfite, 85per cent 在 叔丁醇 、 四氧化锇 dichloromethane ethanol 、 Sodium sulfate-III 作用下， 以 丙酮 为溶剂， 反应 72.25h， 以to give 3-(5,6-dihydroxyhexyl)-1-methyluracil (461 mg, 66% yield) as a colorless oil的产率得到3-(5,6-dihydroxyhexyl)-1-methyluracil
  参考文献：
  名称：

  Amino-alcohol substituted cyclic compounds

  摘要：

  治疗化合物的化学式为：(X)j-(核心部分)，其中j为整数，范围为1到3，核心部分包括一个杂环，其具有一个环或两个融合环，每个环有五个或六个环原子，A是核心部分的碳原子，与(CH.sub.2).sub.m的末端碳原子相连，X具有以下结构，X为外消旋体混合物、R或S对映异构体、溶剂化物、水合物或盐：##STR1## *C是手性碳原子，n为整数，范围为1到4（最好为1到3），(CH.sub.2).sub.n的一个或多个碳原子可能被酮基或羟基取代，m为整数，范围为1到14。独立的，R.sub.1和R.sub.2可能是氢、直链或支链烷基或烯基，长度最长为12个碳原子，或--(CH.sub.2).sub.w R.sub.5，其中w为整数，范围为2到14，R.sub.5为单取代、双取代或三取代或未取代的芳基，R.sub.5上的取代基为羟基、氯、氟、溴或C.sub.1-6烷氧基。或者，R.sub.1和R.sub.2共同形成一个取代或未取代的、饱和或不饱和的杂环基团，其具有4到8个碳原子，N为杂原子。R.sub.3为氢或C.sub.1-3。或者，治疗化合物还可以具有以下化学式：##STR2## R.sub.4为氢、直链或支链烷基或烯基，长度最长为8个碳原子，--(CH.sub.2).sub.w R.sub.5，其中w为整数，范围为2到14，R.sub.5为单取代、双取代或三取代或未取代的芳基，R.sub.5上的取代基为羟基、氯、氟、溴或C.sub.1-6烷氧基，或者为取代或未取代的、饱和或不饱和的杂环基团，其具有4到8个碳原子，r和s分别为整数，范围为1到4，其和(r+s)不大于5。t为整数，范围为1到14，(CH.sub.2).sub.s或(CH.sub.2).sub.t的一个或多个碳原子可能被酮基或羟基取代。

  公开号：

  US05837703A1
• 作为产物：
  描述：

  1-甲基尿嘧啶 、 6-溴-1-己烯 以 二甲基亚砜 为溶剂， 以72%的产率得到3-(5-hexenyl)-1-methyluracil
  参考文献：
  名称：

  Olefin substituted long chain compounds

  摘要：

  公开了一种具有以下结构的烯烃取代化合物：R--（核心基团），其中R是直链碳氢化合物，具有至少一个双键，碳链长度约为6至18个碳原子，多个双键之间至少相隔三个碳原子，最接近核心基团的双键距离核心基团至少五个碳原子，碳氢链可能被羟基、卤素、酮基或二甲氨基基团取代和/或由氧原子中断，以及其盐和药物组合物。

  公开号：

  US05521315A1

文献信息

• Cell signaling inhibitors
  申请人：Cell Therapeutics, Inc.

  公开号：US05470878A1

  公开（公告）日：1995-11-28

  Therapeutic compounds have the formula: (X)j-(non-cyclic core moiety), j being an integer from one to three, the core moiety is non-cyclic and X is a racemic mixture, R or S enantiomer, solvate, hydrate, or salt of: ##STR1## *C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkane or alkene of up to twelve carbon atoms in length, or --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy. Or jointly, R.sub.1 and R.sub.2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R.sub.3 is a hydrogen or C.sub.1-3. Or, therapeutic compounds may also have the formula: ##STR2## R.sub.4 is a hydrogen, a straight or branched chain alkane or alkene of up to eight carbon atoms in length, --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy, or a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms. r and s are independently integers from one to four, the sum (r+s) not being greater than five. t is an integer from one to fourteen and one or more carbon atoms of (CH.sub.2).sub.s or (CH.sub.2).sub.t may be substituted by a keto or hydroxy group.

  治疗性化合物的化学式为：(X)j-(非环核心基团)，其中j为1到3之间的整数，核心基团为非环状，X为一个消旋混合物、R或S对映体、溶剂化合物、水合物或盐类：*C为手性碳原子，n为1到4之间的整数（最好为1到3），(CH.sub.2).sub.n的一个或多个碳原子可被酮基或羟基取代，m为1到14之间的整数。独立地，R.sub.1和R.sub.2可以是氢、直链或支链烷烯链，长度最多为12个碳原子，或--(CH.sub.2).sub.w R.sub.5，其中w为2到14之间的整数，R.sub.5为单取代、双取代或三取代的芳基基团，R.sub.5上的取代基为羟基、氯、氟、溴或C.sub.1-6烷氧基。或者，R.sub.1和R.sub.2共同形成一个取代或未取代、饱和或不饱和的杂环基团，含有4到8个碳原子，N为杂原子。R.sub.3为氢或C.sub.1-3。或者，治疗性化合物也可以具有以下化学式：R.sub.4为氢、直链或支链烷烯链，长度最多为8个碳原子，--(CH.sub.2).sub.w R.sub.5，其中w为2到14之间的整数，R.sub.5为单取代、双取代或三取代的芳基基团，R.sub.5上的取代基为羟基、氯、氟、溴或C.sub.1-6烷氧基，或者为一个取代或未取代、饱和或不饱和的含有4到8个碳原子的杂环基团。r和s独立地为1到4之间的整数，和不大于5。t为1到14之间的整数，(CH.sub.2).sub.s或(CH.sub.2).sub.t的一个或多个碳原子可被酮基或羟基取代。
• Substituted amino alcohol compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05641783A1

  公开（公告）日：1997-06-24

  Disclosed are compounds having a straight or branched aliphatic hydrocarbon structure of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5. If R.sub.1 or R.sub.2 is --(CH.sub.2).sub.w R.sub.5, w may be an integer from one to twenty and R.sub.5 may be an hydroxyl, halo, C.sub.1-8 alkoxyl group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R.sub.1 and R.sub.2 may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocycle. R.sub.3 may be either hydrogen or C.sub.1-3. In the compounds, a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty. R.sub.4 is a terminal moiety comprising a substituted or unsubstituted, oxidized or reduced ring system, the ring system having a single ring or two to three fused rings, a ring comprising from three to seven ring atoms. The disclosed compounds are effective agents to inhibit undesirable responses to cell stimuli.

  本文揭示了具有公式I的直链或支链脂肪烃结构的化合物：##STR1## 在公式I中，n是一个从一到四的整数，m是一个从四到二十的整数。独立地，R.sub.1和R.sub.2是氢，长度最多为二十个碳原子的直链或支链烷基，烯基或炔基，或者是--(CH.sub.2).sub.w R.sub.5。如果R.sub.1或R.sub.2是--(CH.sub.2).sub.w R.sub.5，w可以是一个从一到二十的整数，R.sub.5可以是一个羟基，卤素，C.sub.1-8烷氧基团或一个取代或未取代的碳环或杂环。另外，R.sub.1和R.sub.2可以共同形成一个取代或未取代的，饱和或不饱和的，由四到八个碳原子组成的杂环，N是所得杂环的杂原子。R.sub.3可以是氢或C.sub.1-3。在化合物中，包括R.sub.1或R.sub.2，(CH.sub.2).sub.n和(CH.sub.2).sub.m的碳原子总和不超过四十。R.sub.4是一个末端基团，包括一个取代或未取代的，氧化或还原的环系统，该环系统具有单环或两到三个融合环，一个环包含三到七个环原子。所述化合物是有效的抑制细胞刺激引起的不良反应的药剂。
• Method for preparing substituted amino alcohol compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05777117A1

  公开（公告）日：1998-07-07

  Disclosed is a process for preparing compounds having a straight or branched aliphatic hydrocarbon structure of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5. If R.sub.1 or R.sub.2 is --(CH.sub.2).sub.w R.sub.5, w may be an integer from one to twenty and R.sub.5 may be an hydroxyl, halo, C.sub.1-8 alkoxyl group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R.sub.1 and R.sub.2 may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocyle. R.sub.3 may be either hydrogen or C.sub.1-3. In the compounds, a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty. R.sub.4 is a terminal moiety comprising a substituted or unsubstituted, oxidized or reduced ring system, the ring system having a single ring or two to three fused rings, a ring comprising from three to seven ring atoms. The disclosed compounds are effective agents to inhibit undesirable responses to cell stimuli.

  公开了一种制备具有公式I的直链或支链脂肪族烃结构化合物的过程：##STR1## 在公式I中，n是从一到四的整数，m是从四到二十的整数。独立的，R.sub.1和R.sub.2是氢，长度为二十个碳原子或--（CH.sub.2）.sub.w R.sub.5的直链或支链烷基，烯基或炔基。如果R.sub.1或R.sub.2是--（CH.sub.2）.sub.w R.sub.5，则w可以是从一到二十的整数，R.sub.5可以是羟基，卤素，C.sub.1-8烷氧基或取代或未取代的碳环或杂环。或者，R.sub.1和R.sub.2可以共同形成取代或未取代的，饱和或不饱和的杂环，其具有从四到八个碳原子，N是所得杂环的杂原子。R.sub.3可以是氢或C.sub.1-3。在化合物中，包括R.sub.1或R.sub.2，（CH.sub.2）.sub.n和（CH.sub.2）.sub.m的总碳原子数不超过四十。R.sub.4是一个终端基团，包括一个取代或未取代，氧化或还原的环系统，该环系统具有单个环或两到三个融合的环，一个环包含从三到七个环原子。所公开的化合物是抑制细胞刺激不良反应的有效剂。
• Amino alcohol substituted cyclic compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05801181A1

  公开（公告）日：1998-09-01

  Therapeutic compounds have the formula: (X)j--(core moiety), J being an integer from one to three, the core moiety having at least one, five- to seven-membered ring and X being a racemic mixture, R or S enantiomer, slovate, hydrate, or salt of: ##STR1## *C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkane or alkene of up to twelve carbon atoms in length, or --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy. Or jointly, R.sub.1 and R.sub.2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R.sub.3 is a hydrogen or C.sub.1-3. Or, therapeutic compounds may also have the formula: ##STR2## R.sub.4 is a hydrogen, a straight or branched chain alkane or alkene of up to eight carbon atoms in length, --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy, or a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. r and s are independently integers from one to four, the sum (r+s) not being greater than five. t is an integer from one to fourteen and one or more carbon atoms of (CH.sub.2).sub.s or (CH.sub.2).sub.t may be substituted by a keto or hydroxy group.

  治疗化合物的化学式为：(X)j--(核心基团)，其中J为1到3的整数，核心基团至少有一个5-至七元环，X为立体异构体混合物、R或S对映体、溶剂、水合物或盐，其化学结构如下：##STR1## *C为手性碳原子，n为1到4的整数（最好为1到3），(CH.sub.2).sub.n的一个或多个碳原子可以被酮或羟基取代，m为1到14的整数。独立地，R.sub.1和R.sub.2可以是氢、长度为12个碳原子的直链或支链烷烃或烯烃，或--(CH.sub.2).sub.w R.sub.5，其中w为2到14的整数，R.sub.5为单、二、三取代或未取代的芳基基团，R.sub.5上的取代基为羟基、氯、氟、溴或C.sub.1-6烷氧基。或者，R.sub.1和R.sub.2共同形成一个取代或未取代、饱和或不饱和、碳原子数为4到8的杂环基团，其中N为杂原子。R.sub.3为氢或C.sub.1-3。此外，治疗化合物的化学式也可以为：##STR2## R.sub.4为氢、长度为8个碳原子的直链或支链烷烃或烯烃，或--(CH.sub.2).sub.w R.sub.5，其中w为2到14的整数，R.sub.5为单、二、三取代或未取代的芳基基团，R.sub.5上的取代基为羟基、氯、氟、溴或C.sub.1-6烷氧基，或者为取代或未取代、饱和或不饱和、碳原子数为4到8的杂环基团，其中N为杂原子。r和s分别为1到4的整数，它们的和（r+s）不超过5。t为1到14的整数，(CH.sub.2).sub.s或(CH.sub.2).sub.t的一个或多个碳原子可以被酮或羟基取代。
• Epoxide-containing compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05866576A1

  公开（公告）日：1999-02-02

  Disclosed are enantiomers, diastereomers, salts, solvates, hydrates and mixtures thereof, of formula I: ##STR1## The core moiety is a monocyclic ring structure having five to six ring atoms and two nitrogen atoms at the 1 and 3 positions, n is an integer from 4 to 16, R.sub.1 and R.sub.2 are hydrogen, halogen or C.sub.1-12 alkyl or alkenyl, and (CH.sub.2).sub.n may be optionally substituted by a hydroxyl, halogen, oxygen, a C.sub.1-4 alkyl group or a dimethylamino group. The compounds and pharmaceutical composition thereof are useful in methods for treating an individual having a disease or treatment-induced toxicity mediated through a second messenger.

  本发明涉及公式I的对映体、二对映异构体、盐、溶剂物、水合物和其混合物，其中核心基团为具有五至六个环原子和1和3位置处的两个氮原子的单环环结构，n为4至16的整数，R.sub.1和R.sub.2为氢、卤素或C.sub.1-12烷基或烯基，而(CH.sub.2).sub.n可选择地被羟基、卤素、氧、C.sub.1-4烷基或二甲氨基基团取代。该化合物及其制药组合物在治疗通过第二信使介导的疾病或治疗引起的毒性的个体的方法中有用。